The global science-based health care company reported a 9% increase in sales to $2.8 billion, from $2.6 billion in the prior year reflecting continued sales growth across each of the customer segments. The firm continues to invest strongly in R&D and other critical areas to drive further growth for the long-term. In order to maintain the growth momentum, the firm plans to combine with Organon BioSciences are at an advanced stage.
Sources: Data collected by 123jump.com and Ticker.com from company press releases, filings and corporate websites.
Market data: BATS Exchange. Inc.
350 Fund Managers Interviews - 10-year Annual earnings on 4,600 U.S. companies - 20-quarter Earnings on 3,800 U.S. companies - 3,200 U.S. IPO Prospectuses
- 2,100 Economic data releases from U.S., EU, UK, India, HK and Australia. 10-year Annual reports on 3,500 U.S. companies -
U.S. Earnings Calendar with 4,800 companies - 90,000 10-K reports - 26,000 Global markets news archive - 2,200 Earnings Conference Call Summaries
More:
